Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1996, the company has made significant strides in developing innovative therapies, particularly in the areas of gastrointestinal and ophthalmic disorders. Sucampo is renowned for its flagship product, Amitiza (lubiprostone), which offers unique benefits for patients suffering from chronic constipation and irritable bowel syndrome.
With a strong focus on research and development, Sucampo has established a solid market position, recognised for its commitment to improving patient outcomes through advanced pharmaceutical solutions. The company operates primarily in North America and has expanded its reach into international markets, further solidifying its reputation as a leader in specialty pharmaceuticals.
-4 vs industry average
Sucampo Pharmaceuticals, Inc.’s score of 34 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sucampo Pharmaceuticals, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Sucampo Pharmaceuticals, Inc. yet.
Sucampo Pharmaceuticals, Inc.'s reported carbon emissions
Sucampo Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Mallinckrodt plc, which may influence its climate commitments and emissions reporting.
As of now, Sucampo Pharmaceuticals has not established any documented reduction targets or initiatives related to carbon emissions. The absence of specific emissions data and reduction commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy.
Given its affiliation with Mallinckrodt plc, any potential climate initiatives or emissions data may be inherited from this parent organisation. However, no specific emissions figures or reduction targets have been cascaded from Mallinckrodt plc to Sucampo Pharmaceuticals at this time.
In summary, Sucampo Pharmaceuticals, Inc. is currently lacking in detailed emissions data and formal climate commitments, reflecting a need for further development in its sustainability practices.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sucampo Pharmaceuticals, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Sucampo Pharmaceuticals, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
Inherited from Mallinckrodt plc
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Sucampo Pharmaceuticals, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project